Editas Medicine(US:EDIT)2026-03-09 20:50Financial Performance - The company reported net losses of $160.1 million and $237.1 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $1.6 billion as of December 31, 2025[601]. - The net loss for the year ended December 31, 2025, was $160.1 million, a 32% improvement compared to a net loss of $237.1 million in 2024[625]. - Restructuring and impairment charges increased by $48.4 million to $60.7 million for the year ended December 31, 2025, compared to $12.2 million in 2024[625]. - Total cash, cash equivalents, and marketable securities as of December 31, 2025, amounted to $146.6 million[634]. - Net cash used in operating activities was approximately $165.2 million for the year ended December 31, 2025, compared to $210.3 million for the year ended December 31, 2024, reflecting a 21.4% decrease[640][641]. Revenue Generation - The company has not generated any revenue from product sales to date and does not expect to do so for the foreseeable future[602]. - The company recognized $23.2 million in revenue related to its collaboration with Bristol Myers Squibb (BMS) for the year ended December 31, 2025, with $9.7 million being previously deferred revenue[603]. - Collaboration and other research and development revenues increased by $8.2 million, reaching $40.5 million for the year ended December 31, 2025, a 25% increase from $32.3 million in 2024[626]. Research and Development - The company plans to submit an investigational new drug application for its lead candidate EDIT-401 by mid-2026, aiming for early human proof-of-concept data by the end of 2026[597]. - EDIT-401 has shown an approximately 90% mean reduction in LDL-C levels in preclinical studies, indicating its potential effectiveness[596]. - The company expects to continue incurring significant operating losses as it supports preclinical studies and prepares for clinical development of EDIT-401[601]. - The company anticipates that its research and development expenses will decrease in future periods due to the discontinuation of its ex vivo reni-cel program[609]. Expenses and Cost Management - Research and development expenses decreased by $109.2 million to $89.9 million for the year ended December 31, 2025, a 55% reduction from $199.2 million in 2024[627]. - General and administrative expenses decreased by approximately $22.1 million to $49.9 million for the year ended December 31, 2025, a 31% decrease from $72.0 million in 2024[628]. - Employee-related expenses in research and development decreased by $24.0 million to $30.2 million for the year ended December 31, 2025, a 44% decrease from $54.2 million in 2024[627]. - External research and development expenses decreased by $51.2 million to $27.3 million for the year ended December 31, 2025, a 65% decrease from $78.5 million in 2024[629]. - The total operating expenses decreased by $82.9 million to $200.5 million for the year ended December 31, 2025, a 29% decrease from $283.5 million in 2024[625]. Workforce and Restructuring - The company reduced its workforce by approximately 180 positions, or 65%, as part of the restructuring process initiated in December 2024[613]. - Restructuring charges increased by approximately $48.4 million to $60.7 million for the year ended December 31, 2025, from $12.2 million for the year ended December 31, 2024, representing a 397% increase[632]. Cash Flow and Financing - Net cash provided by investing activities was approximately $138.7 million for the year ended December 31, 2025, primarily from maturities of marketable securities of $139.0 million[642]. - Net cash provided by financing activities was approximately $40.5 million for the year ended December 31, 2025, primarily from net proceeds of $42.8 million from the issuance of common stock[644]. - The company expects to fund its operating expenses and capital expenditures into the third quarter of 2027 with existing cash and cash equivalents[647]. - Future funding requirements will depend on various factors, including the costs of progressing the preclinical and clinical development of EDIT-401[646]. Market Risk and Exposure - The company's primary exposure to market risk is interest rate sensitivity, particularly due to investments in U.S. Treasury and government agency obligations[656]. - An immediate 100 basis point change in interest rates would not have a material effect on the fair market value of the company's investments due to their short-term maturities and low risk profiles[656]. - Substantially all of the company's total liabilities as of December 31, 2025, were denominated in U.S. dollars, indicating minimal exposure to foreign currency exchange rate risk[657].